Orphan drugs in development for urea cycle disorders: current perspectives

References

• Brusilow S, Horwich A. Urea cycle enzymes. In: Scriver C, Beaudet A, Sly W, Valle D, editors. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York: McGraw-Hill; 2001:1909–1963.
   Google Scholar
• Summar ML, Koelker S, Freedenberg D, et al. The incidence of urea cycle disorders. Mol Genet Metab. 2013;110(1–2):179–180.
   PubMed Web of Science ®Google Scholar
• Leonard JV, Morris AA. Urea cycle disorders. Semin Neonatol. 2002;7(1):27–35.
   PubMedGoogle Scholar
• Klaus V, Vermeulen T, Minassian B, et al. Highly variable clinical phenotype of carbamylphosphate synthetase 1 deficiency in one family: an effect of allelic variation in gene expression? Clin Genet. 2009;76(3):263–269.
   Web of Science ®Google Scholar
• Rüegger CM, Lindner M, Ballhausen D, et al. Cross-sectional observational study of 208 patients with non-classical urea cycle disorders. J Inherit Metab Dis. 2014;37(1):21–30.
   PubMed Web of Science ®Google Scholar
• Summar ML, Barr F, Dawling S, et al. Unmasked adult-onset urea cycle disorders in the critical care setting. Crit Care Clin. 2005;21(Suppl 4):S1–S8.
   Web of Science ®Google Scholar
• Braissant O. Current concepts in the pathogenesis of urea cycle disorders. Mol Genet Metab. 2010;100(Suppl 1):S3–S12.
   Google Scholar
• Braissant O, McLin VA, Cudalbu C. Ammonia toxicity to the brain. J Inherit Metab Dis. 2013;36(4):595–612.
   PubMed Web of Science ®Google Scholar
• Butterworth RF. Effects of hyperammonaemia on brain function. J Inherit Metab Dis. 1998;21(Suppl 1):6–20.
   PubMed Web of Science ®Google Scholar
• Kido J, Nakamura K, Mitsubuchi H, et al. Long-term outcome and intervention of urea cycle disorders in Japan. J Inherit Metab Dis. 2012;35(5):777–785.
   Web of Science ®Google Scholar
• Häberle J, Boddaert N, Burlina A, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders. Orphanet J Rare Dis. 2012;7:32.
   PubMed Web of Science ®Google Scholar
• Batshaw ML. Sodium benzoate and arginine: alternative pathway therapy in inborn errors of urea synthesis. Prog Clin Biol Res. 1983;127:69–83.
   PubMedGoogle Scholar
• Batshaw ML, Brusilow SW. Treatment of hyperammonemic coma caused by inborn errors of urea synthesis. J Pediatr. 1980;97(6):893–900.
   Web of Science ®Google Scholar
• Morioka D, Kasahara M, Takada Y, et al. Current role of liver transplantation for the treatment of urea cycle disorders: a review of the worldwide English literature and 13 cases at Kyoto University. Liver Transpl. 2005;11(11):1332–1342.
   PubMed Web of Science ®Google Scholar
• Meyburg J, Hoffmann GF. Liver, liver cell and stem cell transplantation for the treatment of urea cycle defects. Mol Genet Metab. 2010;100(Suppl 1):S77–S83.
   Google Scholar
• Lewis HB. Studies in the synthesis of hippuric acid in the animal organism. J Biol Chem. 1914;18:225–231.
   Google Scholar
• Shiple GJ, Sherwin CP. Synthesis of amino acids in animal organisms. I. Synthesis of glycocol and glutamine in the human organism. J Am Chem Soc. 1922;44:618–624.
   Google Scholar
• Brusilow SW, Valle DL, Batshaw M. New pathways of nitrogen excretion in inborn errors of urea synthesis. Lancet. 1979;2(8140):452–454.
   PubMed Web of Science ®Google Scholar
• Niemi AK, Enns G. Sodium phenylacetate and sodium benzoate in the treatment of neonatal hyperammonemia. NeoReviews. 2006;7(9):e486–e495.
   Google Scholar
• Lichter-Konecki U, Diaz GA, Merritt JL 2nd, et al. Ammonia control in children with urea cycle disorders (UCDs); phase 2 comparison of sodium phenylbutyrate and glycerol phenylbutyrate. Mol Genet Metab. 2011;103(4):323–329.
   PubMed Web of Science ®Google Scholar
• Diaz GA, Krivitzky LS, Mokhtarani M, et al. Ammonia control and neurocognitive outcome among urea cycle disorder patients treated with glycerol phenylbutyrate. Hepatology. 2013;57(6):2171–2179.
   PubMed Web of Science ®Google Scholar
• Smith W, Diaz GA, Lichter-Konecki U, et al. Ammonia control in children ages 2 months through 5 years with urea cycle disorders: comparison of sodium phenylbutyrate and glycerol phenylbutyrate. J Pediatr. 2013;162(6):1234. e1221.
   Web of Science ®Google Scholar
• Berry SA, Lichter-Konecki U, Diaz GA, et al. Glycerol phenylbutyrate treatment in children with urea cycle disorders: Pooled analysis of short and long-term ammonia control and outcomes. Mol Genet Metab. 2014;112(1):17–24.
   PubMed Web of Science ®Google Scholar
• Guffon N, Kibleur Y, Copalu W, Tissen C, Breitkreutz J. Developing a new formulation of sodium phenylbutyrate. Arch Dis Child. 2012;97(12):1081–1085.
   PubMed Web of Science ®Google Scholar
• Rieder M. How sweet it isn’t: a new formulation of sodium phenylbutyrate and the challenge of palatability for medicines for children. Arch Dis Child. 2012;97(12):1080.
   Web of Science ®Google Scholar
• Ah Mew N, Caldovic L. N-Acetylglutamate synthase deficiency: an insight into genetics, epidemiology, pathophysiology, and treatment. Appl Clin Genet. 2011;4:127–135.
   PubMedGoogle Scholar
• Häberle J. Role of carglumic acid in the treatment of acute hyperammonemia due to N-acetylglutamate synthase deficiency. Ther Clin Risk Manag. 2011;7:1–6.
   Google Scholar
• Häberle J. Carglumic acid for the treatment of N-acetylglutamate synthase deficiency and of acute hyperammonemia. Expert Rev Endocrinol Metab. 2012;7:263–271.
   PubMedGoogle Scholar
• Van Leynseele A, Jansen A, Goyens P, et al. Early treatment of a child with NAGS deficiency using N-carbamyl glutamate results in a normal neurological outcome. Eur J Pediatr. Epub November 14, 2013.
   Google Scholar
• Gessler P, Buchal P, Schwenk HU, Wermuth B. Favourable long-term outcome after immediate treatment of neonatal hyperammonemia due to N-acetylglutamate synthase deficiency. Eur J Pediatr. 2010;169(2):197–199.
   PubMed Web of Science ®Google Scholar
• Ah Mew N, McCarter R, Daikhin Y, Nissim I, Yudkoff M, Tuchman M. N-Carbamylglutamate augments ureagenesis and reduces ammonia and glutamine in propionic acidemia. Pediatrics. 2010;126(1):e208–e214.
   PubMed Web of Science ®Google Scholar
• Williams M, Huijmans JG, van Diggelen OP, van der Louw EJTM, De Klerk JBC, Häberle J. Carbamoylphosphate synthase I (CPS 1) deficiency: treatment with carglumic acid (Carbaglu) (abstract). J Inherit Metab Dis. 2010;33:S118.
   Web of Science ®Google Scholar
• Ah Mew N, Daikhin E, Payan I, et al. N-Carbamylglutamate increases ureagenesis in patients with CPSI deficiency (abstract). Mol Genet Metab. 2010;99:207.
   Web of Science ®Google Scholar
• Pekkala S, Martínez AI, Barcelona B, et al. Understanding carbamoyl-phosphate synthetase I (CPS1) deficiency by using expression studies and structure-based analysis. Hum Mutat. 2010;31(7):801–808.
   Web of Science ®Google Scholar
• Erez A, Nagamani SC, Lee B. Argininosuccinate lyase deficiency-argininosuccinic aciduria and beyond. Am J Med Genet C Semin Med Genet. 2011;157(1):45–53.
   Google Scholar
• Erez A, Nagamani SC, Shchelochkov OA, et al. Requirement of argininosuccinate lyase for systemic nitric oxide production. Nat Med. 2011;17(12):1619–1626.
   PubMed Web of Science ®Google Scholar
• Brunetti-Pierri N, Erez A, Shchelochkov O, Craigen W, Lee B. Systemic hypertension in two patients with ASL deficiency: a result of nitric oxide deficiency? Mol Genet Metab. 2009;98(1–2):195–197.
   Web of Science ®Google Scholar
• Nagamani SC, Campeau PM, Shchelochkov OA, et al. Nitric-oxide supplementation for treatment of long-term complications in argininosuccinic aciduria. Am J Hum Genet. 2012;90(5):836–846.
   PubMed Web of Science ®Google Scholar
• Niesters M, Dahan A. Pharmacokinetic and pharmacodynamic considerations for NMDA receptor antagonists in the treatment of chronic neuropathic pain. Expert Opin Drug Metab Toxicol. 2012;8(11):1409–1417.
   PubMed Web of Science ®Google Scholar
• Meyburg J, Hoffmann GF. Liver transplantation for inborn errors of metabolism. Transplantation. 2005;80(Suppl 1):S135–S137.
   Web of Science ®Google Scholar
• Strom SC, Fisher RA, Rubinstein WS, et al. Transplantation of human hepatocytes. Transplant Proc. 1997;29(4):2103–2106.
   PubMed Web of Science ®Google Scholar
• Stephenne X, Najimi M, Smets F, Reding R, de Ville de Goyet J, Sokal EM. Cryopreserved liver cell transplantation controls ornithine transcarbamylase deficient patient while awaiting liver transplantation. Am J Transplant. 2005;5(8):2058–2061.
   PubMed Web of Science ®Google Scholar
• Dhawan A, Mitry RR, Hughes RD. Hepatocyte transplantation for liver-based metabolic disorders. J Inherit Metab Dis. 2006;29(2–3):431–435.
   PubMed Web of Science ®Google Scholar
• Puppi J, Tan N, Mitry RR, et al. Hepatocyte transplantation followed by auxiliary liver transplantation – a novel treatment for ornithine transcarbamylase deficiency. Am J Transplant. 2008;8(2):452–457.
   PubMed Web of Science ®Google Scholar
• Stéphenne X, Najimi M, Ngoc DK, et al. Cryopreservation of human hepatocytes alters the mitochondrial respiratory chain complex 1. Cell Transplant. 2007;16(4):409–419.
   PubMed Web of Science ®Google Scholar
• Puppi J, Strom SC, Hughes RD, et al. Improving the techniques for human hepatocyte transplantation: report from a consensus meeting in London. Cell Transplant. 2012;21(1):1–10.
   PubMed Web of Science ®Google Scholar
• Sokal EM. From hepatocytes to stem and progenitor cells for liver regenerative medicine: advances and clinical perspectives. Cell Prolif. 2011;44(Suppl 1):39–43.
   PubMedGoogle Scholar
• Sandhaus RA. Gene therapy meets stem cells. N Engl J Med. 2012;366(6):567–569.
   Web of Science ®Google Scholar
• Sokal EM. Treating inborn errors of liver metabolism with stem cells: current clinical development. J Inherit Metab Dis. Epub March 26, 2014.
   Google Scholar
• Raper SE, Chirmule N, Lee FS, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab. 2003;80(1–2):148–158.
   PubMed Web of Science ®Google Scholar
• Wang L, Morizono H, Lin J, et al. Preclinical evaluation of a clinical candidate AAV8 vector for ornithine transcarbamylase (OTC) deficiency reveals functional enzyme from each persisting vector genome. Mol Genet Metab. 2012;105(2):203–211.
   PubMed Web of Science ®Google Scholar
• Viecelli HM, Thöny B. Challenges of experimental gene therapy for urea cycle disorders. J Pediatr Biochem. 2014;4(1):65–73.
   Google Scholar
• Lichter-Konecki U, Nadkarni V, Moudgil A, et al. Feasibility of adjunct therapeutic hypothermia treatment for hyperammonemia and encephalopathy due to urea cycle disorders and organic acidemias. Mol Genet Metab. 2013;109(4):354–359.
   Web of Science ®Google Scholar
• Kosenko E, Kaminsky Y, Lopata O, et al. Nitroarginine, an inhibitor of nitric oxide synthase, prevents changes in superoxide radical and antioxidant enzymes induced by ammonia intoxication. Metab Brain Dis. 1998;13(1):29–41.
   Web of Science ®Google Scholar
• Braissant O. Ammonia toxicity to the brain:effects on creatine metabolism and transport and protective roles of creatine. Mol Genet Metab. 2010;100(Suppl 1):S53–S58.
   Google Scholar
• Braissant O, Henry H, Villard AM, et al. Ammonium-induced impairment of axonal growth is prevented through glial creatine. J Neurosci. 2002;22(22):9810–9820.
   Web of Science ®Google Scholar
• Braissant O, Cagnon L, Monnet-Tschudi F, et al. Ammonium alters creatine transport and synthesis in a 3D culture of developing brain cells, resulting in secondary cerebral creatine deficiency. Eur J Neurosci. 2008;27(7):1673–1685.
   PubMed Web of Science ®Google Scholar
• Ratnakumari L, Qureshi IA, Maysinger D, Butterworth RF. Developmental deficiency of the cholinergic system in congenitally hyperammonemic spf mice: effect of acetyl-l-carnitine. J Pharmacol Exp Ther. 1995;274(1):437–443.
   Web of Science ®Google Scholar
• Cagnon L, Braissant O. Role of caspases, calpain and cdk5 in ammonia-induced cell death in developing brain cells. Neurobiol Dis. 2008;32(2):281–292.
   PubMed Web of Science ®Google Scholar
• Cagnon L, Braissant O. CNTF protects oligodendrocytes from ammonia toxicity: intracellular signaling pathways involved. Neurobiol Dis. 2009;33(1):133–142.
   Web of Science ®Google Scholar
• Agusti A, Cauli O, Rodrigo R, Llansola M, Hernandez-Rabaza V, Felipo V. p38 MAP kinase is a therapeutic target for hepatic encephalopathy in rats with portacaval shunts. Gut. 2011;60(11):1572–1579.
   Web of Science ®Google Scholar
• Tanigami H, Rebel A, Martin LJ, et al. Effect of glutamine synthetase inhibition on astrocyte swelling and altered astroglial protein expression during hyperammonemia in rats. Neuroscience. 2005;131(2):437–449.
   Web of Science ®Google Scholar
• Willard-Mack CL, Koehler RC, Hirata T, et al. Inhibition of glutamine synthetase reduces ammonia-induced astrocyte swelling in rat. Neuroscience. 1996;71(2):589–599.
   Web of Science ®Google Scholar